The blockbuster drug cabozantinib was dropped by both GSK and BMS. Exelixis persisted because they saw compelling data in niche indications that larger partners deemed too small or uninteresting. This demonstrates how a smaller biotech's focused conviction can triumph where big pharma loses interest.

When facing a crisis, Fibrogen's CEO decided to shut down discovery research programs. The value inflection opportunity was too far in the future, and capital was better spent on assets with the potential to create more near-term value, ensuring the company's survival.

The CEO attributes their ability to run a more complex and expensive Phase 3 trial to a culture of frugality. By minimizing spending on non-essential overhead ("non-working dollars"), the company could allocate more capital directly to the ambitious clinical program that ultimately proved their hypothesis.

Voyager Therapeutics can't afford massive, long-term clinical trials. Instead, it selects programs where it can use tools like imaging and fluid biomarkers to quickly and efficiently confirm a drug is working as intended. This strategy allows for early de-risking before committing massive capital.

ProKidney made the tough call to stop its second Phase 3 study to save $150-170M. This strategic trade-off allowed them to focus resources on the primary US trial under its RMAT designation and crucially extend their cash runway past the 2027 data readout, a vital move for survival in a tough biotech market.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

The longevity startup deliberately terminated its service for clinics, which was generating predictable revenue, to eliminate distractions. This allowed them to focus 100% on the harder, more valuable R&D of building a proprietary data generation platform for drug development.

The company intentionally makes its early research "harder in the short term" by using complex, long-term animal models. This counterintuitive strategy is designed to generate highly predictive data early, thereby reducing the massive financial risk and high failure rate of the later-stage clinical trials.

PathoQuest's survival depended on a difficult strategic pivot. The company had to abandon its initial, ambitious goal of developing clinical diagnostics for infectious diseases to focus solely on providing QC services to the pharma industry. The CEO admitted that without this tough decision, the company would have failed.